Bristol Myers Squibbvs.Merck & Co.
BMY vs MRK · both in Big pharma, part of the Medicine, pharma & life science value chain: Large, diversified pharmaceutical groups with broad portfolios across therapeutic areas.
Merck & Co. is about 2.5× larger than Bristol Myers Squibb by market cap; Bristol Myers Squibb trades at the lower P/E (14.2 vs 103.9); year to date, Merck & Co. leads (+43.1% vs +24.7%).
Side by side
| BMY | MRK | |
|---|---|---|
| Market cap | $132B | $330B |
| Price | $67.92 | $156.45 |
| Today | +1.0% | +3.8% |
| Return YTD | +24.7% | +43.1% |
| Return 1Y | +40.4% | +72.4% |
| P/E | 14.2 | 103.9 |
| P/S | 2.7 | 5.0 |
| P/B | 5.9 | 7.2 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
Bristol Myers SquibbBMY
Opdivo made the company's name in oncology. Immunology and haematology fill out the portfolio, with neuroscience coming through the pipeline.
Full BMY profile →Merck & Co.MRK
Keytruda is the centre of the oncology business, which sits next to a substantial vaccines portfolio. Animal health forms a third division.
Full MRK profile →More BMY & MRK comparisons
Other head-to-heads in the Big pharma segment.
See where BMY and MRK sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →